Last reviewed · How we verify
PTH134
At a glance
| Generic name | PTH134 |
|---|---|
| Also known as | teriparatid |
| Sponsor | Novartis |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- PaTHway CHINA TRIAL: A Trial to Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism (PHASE3)
- Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis (PHASE3)
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of PTH134 in Post-menopausal Women (PHASE1)
- Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTH134 CI brief — competitive landscape report
- PTH134 updates RSS · CI watch RSS
- Novartis portfolio CI